Twist Bioscience annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Twist Bioscience's operating margin was −36.18% for fiscal 2025.
View full Twist Bioscience company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-09-30 | −36.18% | +34.37 pp |
| 2024 | 2024-09-30 | −70.56% | +18.04 pp |
| 2023 | 2023-09-30 | −88.60% | +26.74 pp |
| 2022 | 2022-09-30 | −115.33% | +0.08 pp |
| 2021 | 2021-09-30 | −115.41% | +40.06 pp |
| 2020 | 2020-09-30 | −155.47% | +44.68 pp |
| 2019 | 2019-09-30 | −200.15% | +77.35 pp |
| 2018 | 2018-09-30 | −277.50% | +265.66 pp |
| 2017 | 2017-09-30 | −543.16% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-06-30 | −30.65% | +0.71 pp |
| Q2 2026 | 2026-03-31 | −41.42% | +3.36 pp |
| Q1 2026 | 2025-12-31 | −31.73% | +7.33 pp |
| Q4 2025 | 2025-09-30 | −30.23% | +12.31 pp |
| Q3 2025 | 2025-06-30 | −31.36% | +77.80 pp |
| Q2 2025 | 2025-03-31 | −44.79% | +20.14 pp |
| Q1 2025 | 2024-12-31 | −39.05% | +26.65 pp |
| Q4 2024 | 2024-09-30 | −42.55% | +32.30 pp |
| Q3 2024 | 2024-06-30 | −109.15% | −13.80 pp |
| Q2 2024 | 2024-03-31 | −64.92% | +37.50 pp |
| Q1 2024 | 2023-12-31 | −65.70% | +16.57 pp |
| Q4 2023 | 2023-09-30 | −74.85% | +24.39 pp |
| Q3 2023 | 2023-06-30 | −95.36% | +13.64 pp |
| Q2 2023 | 2023-03-31 | −102.42% | +23.92 pp |
| Q1 2023 | 2022-12-31 | −82.28% | +50.86 pp |
| Q4 2022 | 2022-09-30 | −99.24% | +5.66 pp |
| Q3 2022 | 2022-06-30 | −109.00% | +11.28 pp |
| Q2 2022 | 2022-03-31 | −126.34% | −4.54 pp |
| Q1 2022 | 2021-12-31 | −133.13% | −16.69 pp |
| Q4 2021 | 2021-09-30 | −104.90% | −31.00 pp |
| Q3 2021 | 2021-06-30 | −120.28% | +12.68 pp |
| Q2 2021 | 2021-03-31 | −121.79% | +44.48 pp |
| Q1 2021 | 2020-12-31 | −116.45% | +208.83 pp |
| Q4 2020 | 2020-09-30 | −73.90% | +126.72 pp |
| Q3 2020 | 2020-06-30 | −132.96% | +73.82 pp |
| Q2 2020 | 2020-03-31 | −166.27% | +27.45 pp |
| Q1 2020 | 2019-12-31 | −325.27% | −126.03 pp |
| Q4 2019 | 2019-09-30 | −200.62% | +33.76 pp |
| Q3 2019 | 2019-06-30 | −206.77% | +60.56 pp |
| Q2 2019 | 2019-03-31 | −193.72% | +75.79 pp |
| Q1 2019 | 2018-12-31 | −199.24% | +189.14 pp |
| Q4 2018 | 2018-09-30 | −234.38% | — |
| Q3 2018 | 2018-06-30 | −267.33% | — |
| Q2 2018 | 2018-03-31 | −269.51% | — |
| Q1 2018 | 2017-12-31 | −388.38% | — |
Over the last five reported fiscal years, Twist Bioscience's operating margin increased from −155.47% to −36.18%, a change of +119.29 percentage points. The latest reported quarter, Q3 2026, shows −30.65%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Twist Bioscience filings at SEC.gov ↗